Ligand Pharmaceuticals (LGND) Competitors

ADMA Biologics (NASDAQ:ADMA) and Ligand Pharmaceuticals (NASDAQ:LGND) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, media sentiment, profitability, analyst recommendations, risk, institutional ownership and dividends.

Which has preferable earnings & valuation, ADMA or LGND?

ADMA Biologics has higher revenue and earnings than Ligand Pharmaceuticals. Ligand Pharmaceuticals is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$426.45M	9.96	$197.67M	$0.86	20.70
Ligand Pharmaceuticals	$167.13M	18.66	-$4.03M	-$4.00	-39.77

Is ADMA or LGND more profitable?

ADMA Biologics has a net margin of 44.06% compared to Ligand Pharmaceuticals' net margin of -40.44%. ADMA Biologics' return on equity of 41.01% beat Ligand Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	44.06%	41.01%	28.47%
Ligand Pharmaceuticals	-40.44%	-9.21%	-8.09%

Which has more risk and volatility, ADMA or LGND?

ADMA Biologics has a beta of 0.38, suggesting that its stock price is 62% less volatile than the S&P 500. Comparatively, Ligand Pharmaceuticals has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500.

Do institutionals and insiders hold more shares of ADMA or LGND?

75.7% of ADMA Biologics shares are held by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are held by institutional investors. 3.5% of ADMA Biologics shares are held by insiders. Comparatively, 7.0% of Ligand Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Do analysts rate ADMA or LGND?

ADMA Biologics currently has a consensus target price of $27.67, suggesting a potential upside of 55.43%. Ligand Pharmaceuticals has a consensus target price of $157.00, suggesting a potential downside of 1.31%. Given ADMA Biologics' stronger consensus rating and higher probable upside, research analysts clearly believe ADMA Biologics is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33
Ligand Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media favor ADMA or LGND?

In the previous week, ADMA Biologics had 3 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 12 mentions for ADMA Biologics and 9 mentions for Ligand Pharmaceuticals. ADMA Biologics' average media sentiment score of 1.59 beat Ligand Pharmaceuticals' score of 1.32 indicating that ADMA Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	12 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Ligand Pharmaceuticals	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

ADMA Biologics beats Ligand Pharmaceuticals on 12 of the 17 factors compared between the two stocks.